Table 4. Correlation between ESR1, CYP2C19, UGT2B15 polymorphisms and clinicopathological features.

	ESR1 PvuII			CYP2C19			UGT2B15
	wt/vt vt/vt	wt/wt	P	wt/wt	wt/*2 *2/*2	P	wt/wt	wt/*2 *2/*2	P
T stage
T1-2	43	18	0.15	51	10	0.68	15	46	0.09
T3-4	3	4		6	1		4	3
N stage
N0	34	16	0.51	41	9	0.43	13	37	0.51
N1	11	6		15	2		5	12
Grading
G1-2	20	6	0.31	21	5	0.59	6	20	0.31
G3	9	5		11	3		5	9
Histological type
Ductal	30	11	0.49	32	9	0.04	14	28	0.27
Lobular	11	5		16	0		3	12
ER status
0	12	6	0.55	15	3	0.62	7	11	0.22
1	35	16		42	9		13	38
PR status
0	9	11	0.01	18	2	0.25	7	14	0.40
1	38	11		39	10		13	35
HER2 status
0	31	12	0.54	36	7	0.49	14	28	0.34
1	7	2		7	2		2	8
Age
<50 yr.	10	6	0.40	13	3	0.57	4	11	0.55
≥50 yr.	37	16		44	9		16	38
Molecular subtype
Luminal A	10	2	0.72	9	3	0.73	3	9	0.31
Luminal B (HER2-)	9	2		10	1		3	8
Luminal B (HER2+)	7	2		7	2		2	7
HER2+	0	0		0	0		0	1
Triple negative	2	2		4	0		3	1
Recurrence
Yes	40	13	0.02	43	10	0.43	13	40	0.12
No	7	9		14	2		7	9
Death
Yes	42	17	0.17	49	10	0.56	16	43	0.32
No	5	5		8	2		4	6